Tebentafusp (Kimmtrak)

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

Mechanism of action

Bispecific protein consisting of an affinity-enhanced T-cell receptor fused to an anti-CD3 effector that can redirect T cells to target glycoprotein 100-positive cells.

Diseases for which it is used

History of changes in FDA indication

  • 1/25/2022: Approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. (Based on IMCgp100-202)

Also known as

  • Code name: IMCgp100
  • Generic name: tebentafusp-tebn
  • Brand name: Kimmtrak